ASH 2025 | NUTRIVENTION-5: a dietary intervention for NDMM with standard induction chemotherapy

Hi, I’m Urvi Shah, a hematologist and oncologist at Memorial Sloan Kettering Cancer Center with an interest in modifiable risk factors and how these affect cancer risk progression and survival. We did the pilot NUTRIVENTION study, which was just published in Cancer Discovery, where we looked at a population with MGUS and smoldering myeloma and how a high-fiber dietary intervention could potentially improve biomarkers of progression, such as the microbiome, immune-like inflammation and metabolism, such as insulin resistance. And we do show in some patients there may be a delay in progression to the cancer myeloma. Building on this trial, we have built a newly diagnosed study based on also preclinical work in the paper where we show that in mouse models, a high fiber diet may also delay progression. In newly diagnosed myeloma, when patients are on induction therapy with daratumumab, lenalidomide, bortezomib, and dexamethasone, the standard practice is to just give the chemotherapy and watch for response. What we will be doing in this study is to understand how dietary interventions affect response and quality of life while on treatment. Participants will be patients who are getting four cycles of Dara-RVD and during that half of the patients will be randomized to receive a high fiber dietary intervention where we will provide food lunch and dinner for 12 weeks and in the usual care arm they will receive information about the intervention after 12 weeks. And in the usual care arm, they will receive information about the intervention after 12 weeks. And they will also receive a gift card of $200. So both arms are getting some aspect of the intervention. One is during the induction chemotherapy and one is after the induction chemotherapy. We are also looking at things like the microbiome, quality of life, and other aspects of biomarkers. If patients are interested in taking part in this study, they can be getting treatment at any academic myeloma center across the United States as long as their center uses EPIC as the electronic medical record where they are getting treatment. And they also reach out to us before cycle one, day 15 of their treatment. So early on in their treatment course. If they’ve gotten one or two doses of CyBorD or other treatment, they may still be eligible. So feel free to reach out to us if you’re interested. We’d love to have doctors as collaborators as well from these institutions. So if you think you may have enough patients who are interested in enrolling on this study, please reach out. This is a decentralized study, which means that the patients do not have to come to Memorial Sloan Kettering, and we will consent the patients remotely and provide the intervention to the participants remotely. You could email ShahNutrivention@mskcc.org if you are interested in learning more about the study or if you may think you’re a candidate or have patients to refer.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.